Keen Vision Acquisition CORP Form 4 insider transactions

Mederas Novoheart and Curi Bio have partnered to integrate their technologies, aiming to accelerate and improve the efficiency of human-based cardiac drug screening.

Medera's Novoheart has launched CTScreen v1.5, an advanced automated cardiac screening platform, which has been adopted by AstraZeneca to enhance human heart-based drug testing.

Medera and the Cardiovascular Disease National Collaborative Enterprise (CADENCE) have initiated Asia's first cardiac gene therapy clinical trial for heart failure in Singapore, marking a significant step in global cardiovascular research.

Medera's Novoheart subsidiary leverages AI and machine learning to enhance drug screening with human mini-Heart technology, potentially reducing costs and improving clinical trial success rates.

Medera's gene therapy subsidiary, Sardocor Corp., has completed Cohort A and initiated dosing in Cohort B of its MUSIC-HFpEF Phase 1/2a clinical trial evaluating SRD-002 for Heart Failure with Preserved Ejection Fraction (HFpEF).

Keen Vision Acquisition Corporation (KVAC) and Medera Inc. have entered into a definitive merger agreement, aiming to list Medera on NASDAQ with an implied initial enterprise value of approximately $622.6 million.

Medera Inc., a clinical-stage biotechnology company, is set to go public on the NASDAQ through a merger with Keen Vision Acquisition Corporation, targeting difficult-to-treat cardiovascular diseases.